Assembly Biosciences: Funding, Investors & Team (Sep 2026)
Assembly Biosciences is a public biotechnology company developing two innovative platform programs: an HBV program advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and a microbiome program developing novel oral biotherapeutics designed to address diseases associated with the microbiome. Assembly‘s HBV program is advancing multiple drug candidates with the aim of increasing cure rates in patients with chronic HBV. The company's microbiome program consists of a fully integrated platform that includes a robust strain identification and selection process, methods for strain isolation and growth under current Good Manufacturing Practices and a patent-pending delivery system, GEMICEL®, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract. The lead program from this platform is in development for the treatment of C. difficile infections. Assembly is also developing additional microbiome product candidates.
Assembly Biosciences has raised $115M across 1 funding round on record, the most recent an undisclosed round of $115M announced in May 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Assembly Biosciences Company Profile and Key Stats
Latest funding round on record: May 2026.
Assembly Biosciences Funding Rounds
Assembly Biosciences Founders and Leadership Team
Contact details for the Assembly Biosciences team: 1 of 1 has an email address on file, 1 has a LinkedIn profile.
Start 14-day free trial →Assembly Biosciences Funding Compared to Other Biotechnology Startups
Assembly Biosciences' latest round of $115M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Assembly Biosciences in Biotechnology and Carmel
Companies Similar to Assembly Biosciences
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Assembly Biosciences Funding FAQs
What does Assembly Biosciences do?
Assembly Biosciences is a public biotechnology company developing two innovative platform programs: an HBV program advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and a microbiome program developing novel oral biotherapeutics designed to address diseases associated with the microbiome. Assembly‘s HBV program is advancing multiple drug candidates with the aim of increasing cure rates in patients with chronic HBV. The company's microbiome program consists of a fully integrated platform that includes a robust strain identification and selection process, methods for strain isolation and growth under current Good Manufacturing Practices and a patent-pending delivery system, GEMICEL®, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract. The lead program from this platform is in development for the treatment of C. difficile infections. Assembly is also developing additional microbiome product candidates.
How much funding has Assembly Biosciences raised?
Assembly Biosciences has raised $115M across 1 round on record. The most recent is an undisclosed round of $115M announced in May 2026.
When did Assembly Biosciences last raise funding?
Assembly Biosciences' most recent funding round on record is an undisclosed round of $115M, announced in May 2026.
Who founded Assembly Biosciences?
FundedIQ lists William Delaney (Founder) at Assembly Biosciences.
Where is Assembly Biosciences headquartered?
Assembly Biosciences is based in Carmel, Indiana, United States.
How many employees does Assembly Biosciences have?
Assembly Biosciences is in the 101-250 employee band.
How does Assembly Biosciences' funding compare to other Biotechnology startups?
Assembly Biosciences' latest round of $115M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Assembly Biosciences Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Assembly Biosciences is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.